ITEMS IN AFP WITH KEYWORD:
Cholecalciferol (vitamin D3) supplementation should be used for vitamin D repletion because it may be more effective in preventing nonvertebral fractures.
Upper respiratory tract infections account for millions of visits to family physicians each year in the United States. Although warranted in some cases, antibiotics are greatly overused. This article outlines the guidelines and indications for appropriate antibiotic use for common upper respiratory ...
Mar 15, 2012 Issue
Medications for Weight Loss in Patients with Type 2 Diabetes Mellitus [FPIN's Clinical Inquiries]
Fluoxetine (Prozac) and orlistat (Xenical) produce modest short-term weight loss, but their long-term benefits are unclear and their safety is uncertain.
Oct 1, 2011 Issue
Improving Medication Adherence in Patients with Comorbidities [FPIN's Clinical Inquiries]
Interventions that involve pharmacists to review, simplify, and monitor medication use significantly improve adherence in patients with multiple medical conditions.
Phentermine and diethylpropion are appetite suppressants approved for use in the United States as adjuncts in the treatment of obesity. These agents demonstrate a modest weight loss benefit when combined with dietary modifications and exercise.
Mar 15, 2011 Issue
Antibiotics for Viral Upper Respiratory Tract Infections in Children [FPIN's Clinical Inquiries]
Antibiotic therapy does not benefit children with bronchiolitis, the common cold, or nonstreptococcal pharyngitis. If purulent rhinitis is present for more than 10 days, antibiotics shorten the duration of runny nose symptoms.
Dec 15, 2010 Issue
Thiazolidinedione Therapy for Managing Metabolic Syndrome [FPIN's Clinical Inquiries]
There is no patient-oriented evidence supporting the use of TZD therapy in patients in the general population who have metabolic syndrome. Rosiglitazone (Avandia) use decreases cardiovascular morbidity and mortality in patients with metabolic syndrome who are undergoing coronary stenting.
Our society values brand-name products, and drugs are no exception. However, only rudimentary safety information is available for new drugs. Required safety studies are short-term and may involve only 100 to 300 patients. Randomized controlled trials, the gold standard for testing effectiveness, may also be short-term.
At the time of launch, a new drug usually has not been as widely tested as other available therapies, and there is often insufficient good-quality published evidence to adequately judge its true effectiveness and safety. A careful and critical approach to the assessment and prescription of new drugs is needed to ensure their use is appropriate.